PMC:7784830 / 7953-8119 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7784830","sourcedb":"PMC","sourceid":"7784830","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7784830","text":"Further, proteins such as brilacidin [44] and recombinant protein AT-100 [50] are being developed by Innovation Pharmaceuticals and Airway Therapeutics, respectively.","tracks":[{"project":"LitCovid-sentences","denotations":[{"id":"T66","span":{"begin":0,"end":166},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T66","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-sentences","color":"#db93ec","default":true}]}]}}